ClinicalTrials.gg
CompletedNCT02121717CMAPUpdated Oct 25, 2019

Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

A Phase 3 interventional study of Chiglitazar and Placebo in Type 2 Diabetes, sponsored by Chipscreen Biosciences, Ltd.. Completed at 26 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-10-25.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
535
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
158th of 767
535 · median 199
Started
2014
with 31 others
Phase 3
207 of 909
38 open now
Registered
192nd of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 158th largest by enrollment of the 767 interventional ones that give a count, is one of 32 that started in 2014, is one of 207 in phase 3, and was the 192nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with placebo.

Read the detailed description

The efficacy and safety will be compared between Chiglitazar and placebo after treatment of 24 weeks. The long term efficacy and safety of Chiglitazar will be evaluated after 52 weeks treatment.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Chiglitazar,diabetes,type 2 diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the WHO Diagnostic Criteria for Type 2 Diabetes (published on 1999);
  2. ≥ 7.5% and ≤ 10.0% after control of diet and exercises;
  3. Male and female,age between 18 and 70 years;
  4. between 18.5-35kg/m2;
  5. Willing to be assigned to any treatment arm and sign inform consent.

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes;
  2. Treated by oral or injective antidiabetic drug before screening, including insulin and herb;
  3. Fasting plasma glucose > 13.3 mmol/L (240 mg/dL);
  4. Resistant hypertension [blood pressure above the goal despite adherence to at least 3 optimally dosed antihypertensive medications (including diuretic) of different classes,or blood pressure is controlled to below the goal by at least 4 different classes of drugs];
  5. Plasma triglyceride > 500 mg/dL (5.65 mmol/L);
  6. Is treating by fibrates;
  7. History of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy;
  8. Had ,cerebrovascular accident or unstable angina in the past 6 months;
  9. History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery;
  10. Heart failure ( classification Stage III or IV), or left ventricular hypertrophy indicated by ;
  11. Hepatic diseases such as hepatocirrhosis, active hepatitis, or alanine aminotransferase > 2.5 fold of the ;
  12. Kidney diseases or serum creatinine exceed the normal range: male > 133 μmol/L or female >108 μmol/L;
  13. Had in the past 5 years, not including basal cell carcinoma;
  14. Had or is currently receiving treatment that can alter blood glucose metabolism, including but not limited to diuretic,hormone (corticotropin or ),beta blockers;
  15. Have the diseases that can alter blood glucose metabolism, including but not limited to active hepatitis, hyperthyroidism,or adrenal tumors;
  16. Edema with unknown reason;
  17. Alcohol or drug addiction;
  18. Had participated other drugs' clinical trials in the 3 months before screening;
  19. Pregnant or lactic women; or women of childbearing age who are not able to or is not willing to conduct ;
  20. Any condition that make investigator consider the subject is not suitable to participate the trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
535 participants (actual)

Study arms

  • Experimental
    Arm 1

    Patients administrate Chiglitazar 32mg once daily for 52 weeks

    Drug: Chiglitazar

  • Experimental
    Arm 2

    Patients administrate Chiglitazar 48mg once daily for 52 weeks

    Drug: Chiglitazar

  • Placebo comparator
    Arm 3

    Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly.

    Drug: Chiglitazar · Drug: Placebo

Interventions

  • Take orally

    Also known as: CS038

  • DrugPlacebo

    Take orally

    Also known as: Plb

06

What researchers measure

Primary outcomes

  1. Change in HbA1c from baseline after 24 weeks of treatment

    The change of HbA1c at week 24 from baseline

    Time frame: 24 weeks

Secondary outcomes

  1. Change in HbA1c from baseline for patients with a baseline HbA1c >=8.5%

    The change of HbA1c at week 24 from baseline for patients with a HbA1c \>=8.5% at baseline

    Time frame: 24 weeks

  2. Change in HbA1c from baseline in patients with a baseline HbA1c < 8.5%

    The change of HbA1c at week 24 from baseline for patients with a HbA1c \< 8.5% at baseline

    Time frame: 24 weeks

  3. Change in HbA1c from baseline

    The change of HbA1c at week 12 from baseline

    Time frame: 12 weeks

  4. Change in HbA1c from baseline

    The change of HbA1c at week 52 from baseline

    Time frame: 52 weeks

  5. Percentage of patients that attained target HbA1c <7.0%

    Percentage of patients whose HbA1c at week 24 are \< 7.0%

    Time frame: 24 weeks

  6. Percentage of patients whose HbA1c lowered by at least 0.5%

    Percentage of patients whose change of HbA1c at week 24 from baseline are \>= 0.5%

    Time frame: 24 weeks

  7. Change in fasting plasma glucose from baseline

    The change of fasting plasma glucose at week 12 and 24 from baseline

    Time frame: 12,24 and 52 weeks

  8. Change in 2-h postprandial glucose (2hPPG) from baseline

    The change of 2-h postprandial glucose (2hPPG) at week 12, 24 and 52 from baseline

    Time frame: 12, 24 and 52 weeks

  9. Change in total cholesterol (TC) from baseline

    The change of total cholesterol (TC) at week 12, 24 and 52 from baseline

    Time frame: 12, 24 and 52 weeks

  10. Change in triglyceride from baseline

    The change of triglyceride at week 12, 24 and 52 from baseline

    Time frame: 12,24 and 52 weeks

  11. Change in high density lipoprotein cholesterol (HDL-C)from baseline

    The change of high density lipoprotein cholesterol (HDL-C) at week week 12, 24 and 52 from baseline

    Time frame: 12, 24 and 52 weeks

  12. Change in low density proprotein cholesterol (LDL-C) from baseline

    The change of low density lipoprotein cholesterol (LDL-C) at week 12, 24 and 52 from baseline

    Time frame: 12, 24 and 52 weeks

  13. Change in free fatty acid (FFA) from baseline

    The change of free fatty acid (FFA) at week 12, 24 and 52 from baseline

    Time frame: 12, 24 and 52 weeks

  14. Change in fasting plasma insulin from baseline

    The change of fasting plasma insulin at week 12, 24 and 52 from baseline

    Time frame: 12, 24 and 52 weeks

  15. Insulin sensitivity assessed by the homeostatic model assessment (HOMA) at 12,24 and 52 weeks, compared with that of baseline

    The change of insulin sensitivity at week 12, 24 and 52 from baseline

    Time frame: 12, 24 and 52 weeks

  16. Change in blood pressure from baseline

    The change of blood pressure at week 24 from baseline

    Time frame: 24 weeks

  17. Percentage of patients who use rescue therapy

    The percentage of patients who use rescue therapy during the 52 weeks of treatment

    Time frame: 52 weeks

07

Study locations

26 sites
  • Peking University Shougang Hospital
    Beijing, Beijing 100000, China
  • China Meitan General Hospital
    Beijing, Beijing 100028, China
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
  • The 306th Hospital of PLA
    Beijing, Beijing 100101, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400016, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400016, China
  • Chongqing Three Gorges Central Hospital
    Chongqing, Chongqing 404000, China
  • Cangzhou's Central Hospital
    Cangzhou, Hebei 061110, China
  • Harrison International Peace Hospital
    Hengshui, Hebei 053000, China
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050051, China
  • Tangshan Gongren Hospital
    Tangshan, Hebei 063000, China
  • The First Affiliated Hospital of Ha'erbin Medical University
    Ha'erbin, Heilongjiang 150081, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430071, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410001, China
  • Chenzhou First People's Hospital
    Chenzhou, Hunan 423000, China
  • Baogang Hospital of Inner Mongilia
    Baotou, Inner Mongolia 014010, China
  • The people's Hospital of Jiangsu Province
    Nanjing, Jiangsu 210029, China
  • The Affiliated Hospital of Xuzhou Medical College
    Xuzhou, Jiangsu 221000, China
  • The Second Hospital of Jilin University
    Changchun, Jilin 130041, China
  • The Affiliated Hospital of Qingdao Medical University
    Qingdao, Shandong 266071, China
  • Zhongshan Hospital Fudan University
    Shanghai, Shanghai 200032, China
  • Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200092, China
  • The Central Hospital of Yangpu District of Shanghai
    Shanghai, Shanghai 200433, China
  • The First Affiliated Hospital of The 4th Military Medical University
    Xi'an, Shanxi 710032, China
  • Huaxi Hopsital of Sichuan University
    Chengdu, Sichuan 610041, China
  • The General Hospital of Tianjin Medical University
    Tianjin, Tianjin 300052, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Nov 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2014
First posted
Apr 23, 2014
Start
Jun 2014
Primary completionActual
Nov 2017
CompletionActual
Nov 2017
Last update
Oct 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02121717
Responsible party
Sponsor
First posted
Apr 23, 2014
Start date
Jun 2014
Primary completion
Nov 2017
Completion
Nov 2017
Last update
Oct 25, 2019

Study contacts

Linong Ji, Dr.
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiglitazar

Start the discussion